Bayer expects to ‘significantly contain’ litigation risk by end of 2026

CEO Bill Anderson addressed the litigations in the United States. “We’re convinced our multi-pronged strategy is the right one. As we continue to advance it, we’ll continuously adjust our approaches to resolution.” Bayer (BAYRY) is making significant progress, Anderson said, adding that he is confident the company will be able to significantly contain the litigation risk by the end of 2026. “Overall, we know that we have a crucial and highly dynamic phase ahead of us,” Anderson explained. This dynamic is reflected in the company’s provisions, which were adjusted upwards over the past quarter due to a range of factors, he noted. For example, Bayer recently announced that it had reached a number of settlements, and, as expected, this was then followed by a moderate increase in glyphosate case filings. This in turn led to additional provisions and higher litigation costs, as did the negative verdict recently issued by the Washington Supreme Court in the Erickson PCB case. The company will continue to evaluate all options to significantly contain the litigation risk.